Wednesday Apr 9
Low-dose lenalidomide plus cytarabine induce complete remission that...
Patients aged 70 years with a World Health Organization diagnosis of AML , without isolated 5q abnormalities, were eligible.
Applied Clinical Trials
Ambit Announces Initiation Of Phase 2 Cohort In MD Anderson Sponsored ...
MD Anderson Cancer Center. Dr. Cortes is also the principal investigator of the upcoming Phase 3 QUANTUM-R trial, the Company's randomized trial comparing quizartinib to standard chemotherapy in FLT3-ITD positive AML patients over the age of 18 who have relapsed from, or are refractory to, frontline chemotherapy, including those patients relapsing ... (more)